Symbols

VTGN

Vistagen·NASDAQ

--(--)

VTGN fundamentals

VTGN Q3 2026 Earnings

Vistagen (VTGN) released its earnings on Feb 12, 2026: revenue was 303.00K (YoY +29.49%), missed estimates; EPS was -0.45 (YoY +2.17%), beat estimates.

Revenue / YoY

303.00K

+29.49%

EPS / YoY

-0.45

+2.17%

Report date

Feb 12, 2026

VTGN Earnings Call Summary for Q3,2026

PALISADE-3 Completion: Randomized portion finalized with operational refinements for PALISADE-4, including AI/ML-driven statistical model optimization.
Women's Health Milestone: Refisolone IND submission planned for Q2 2026, targeting menopausal hot flashes as a hormone-free alternative.
Cash Position Strength: $61.8 million as of Q3 2026, supporting clinical trials and cost-efficient operations.
Regulatory Risk: FDA approval of PALISADE-4 statistical modifications required; PALISADE-2 alone insufficient for NDA submission.
Enrollment Stability: PALISADE-4 recruitment unaffected by PALISADE-3 results; open-label extension provides real-world safety insights.

Earnings

EPS

Revenue

Revenue & Expenses

VTGN has released its 2026 Q3 earnings report, with revenue of 303.00K, reflecting a YoY change of 29.49%, and net profit of -18.90M, showing a YoY change of -34.14%. The Sankey diagram below clearly presents VTGN's revenue sources and cost distribution.

Key Indicators

Vistagen (VTGN) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Vistagen (VTGN)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Vistagen (VTGN)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Vistagen (VTGN)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown